BTX - BioTime, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
2.300
-0.010 (-0.43%)
As of 3:37PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.310
Open2.320
Bid2.320 x 800
Ask2.330 x 1100
Day's Range2.285 - 2.350
52 Week Range1.980 - 3.160
Volume399,156
Avg. Volume540,632
Market Cap291.817M
Beta3.21
PE Ratio (TTM)N/A
EPS (TTM)-1.015
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.75
Trade prices are not sourced from all markets
  • Business Wire9 hours ago

    BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the Board of Directors has implemented a new leadership structure under which Brian Culley has been appointed as the Company’s Chief Executive Officer and as a member of its Board of Directors, effective September 17, 2018. Mr. Culley succeeds Co-CEOs Adi Mohanty and Dr. Michael West.

  • Business Wire2 days ago

    BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors intends to set a new record date for the distribution of AgeX Therapeutics, Inc. (“AgeX”) shares to BioTime shareholders. The ratio of one share of AgeX common stock for every 10 shares of BioTime common stock will remain unchanged.

  • Can The Uptrend Continue for BioTime (BTX)?
    Zacks14 days ago

    Can The Uptrend Continue for BioTime (BTX)?

    Investors certainly have to be happy with BioTime, Inc. (BTX) and its short term performance.

  • Business Wire14 days ago

    BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence

    ALAMEDA, Calif.-- -- Proceeds provide sufficient capital to fund BioTime through major milestones for current programs, including Renevia ® and OpRegen ® key data and decisions BioTime and its shareholders participate in potential Juvenescence upside after conversion of note upon Juvenescence IPO BioTime and its shareholders continue to participate in potential AgeX upside from retained share ownership ...

  • Business Wire21 days ago

    BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences

    ALAMEDA, Calif.-- -- Adi Mohanty to participate in panel discussion at the Annual B. Riley FBR Healthcare Conference Adi Mohanty and Russell Skibsted to host investor one-on-one meetings at the Annual B. Riley FBR Healthcare Conference Adi Mohanty and Russell Skibsted to host investor one-on-one meetings at the 20 th Annual Rodman & Renshaw Global Investment Conference BioTime, Inc. , a clinical-stage ...

  • GlobeNewswire26 days ago

    Research Report Identifies Cloudera, Snap, Social Reality, BioTime, Renewable Energy Group, and Mattel with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cloudera, ...

  • Business Wirelast month

    AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance

    AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), focused on the development and commercialization of novel therapeutics targeting human aging, today announced that it has acquired certain patents and patent applications from Escape Therapeutics relating primarily to the use of the HLA-G gene to suppress rejection of transplanted cells and tissues. The Company plans to utilize the technology in conjunction with its pluripotent stem cell platform for applications in regenerative medicine.

  • Business Wirelast month

    BioTime to Present Data at the Military Health System Research Symposium

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will be presenting a poster at the Military Health System Research Symposium (MHSRS) from August 20-23, 2018 in Kissimmee, Florida. The poster presentation is titled, “Next generation disease modifying viscosupplementation to delay or prevent invasive surgery in combat-related Post Traumatic Osteoarthritis (PTOA).” Dr. Thomas Zarembinski, PhD, MBA and Head of External R&D for BioTime will present the data on Tuesday, August 21st during the Extremity and Craniomaxillofacial Regeneration session. The poster describes the ability of a novel DNA-based small molecule to decrease cartilage degradation and turnover normally associated with osteoarthritis as well as the ability of BioTime’s proprietary HyStem® drug delivery platform to modulate its release over an extended period.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of BTX earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 BioTime Inc Earnings Call

  • BioTime (BTX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    BioTime (BTX) Reports Q2 Loss, Tops Revenue Estimates

    BioTime (BTX) delivered earnings and revenue surprises of 33.33% and 671.82%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    BioTime: 2Q Earnings Snapshot

    The Alameda, California-based company said it had a loss of 3 cents per share. Losses, adjusted for non-recurring gains, were 6 cents per share. The biotechnology company posted revenue of $2.5 million ...

  • Business Wire2 months ago

    BioTime Reports Second Quarter Results and Recent Corporate Accomplishments

    ALAMEDA, Calif.-- -- BioTime to receive $43 million from Juvenescence BioTime shareholders to receive one share of AgeX common stock for every 10 shares of BioTime common stock held BioTime clinical programs including OpRegen ® for dry-AMD and Renevia ® for volume enhancement are on track Conference call and webcast today at 1:30pm PT/4:30pm ET BioTime, Inc.  , a clinical-stage biotechnology company ...

  • ACCESSWIRE2 months ago

    BioTime, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / BioTime, Inc. (NYSE MKT: BTX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. To ...

  • Business Wire2 months ago

    BioTime to Receive $43 Million From Juvenescence

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced a new strategic alignment between AgeX Therapeutics and Juvenescence Limited, a global leader in developing therapeutics focused on improving and extending human lifespans.

  • Business Wire2 months ago

    BioTime Announces the Start of an Investigator Initiated Study of Premvia™ Designed and Conducted by Dr. Gordon H. Sasaki

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported that Gordon H. Sasaki, M.D., F.A.C.S., has initiated his independent investigator-initiated study of Premvia™ combined with the patient’s own fat for volume augmentation of the hand. Dr. Sasaki is a board-certified plastic surgeon serving Los Angeles and Pasadena, California.

  • Business Wire2 months ago

    BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the distribution ratio for the distribution of AgeX Therapeutics shares owned by BioTime on a pro-rata basis to eligible BioTime shareholders.

  • Business Wire2 months ago

    Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27th – October 30th, 2018, in Chicago, Illinois. “We are delighted that the AAO has accepted our abstract for an oral presentation at the upcoming meeting,” said Adi Mohanty, Co-Chief Executive Officer of BioTime.

  • Here's Why BioTime, Inc Rose as Much as 14.3% Today
    Motley Fool2 months ago

    Here's Why BioTime, Inc Rose as Much as 14.3% Today

    The small-cap biopharma company issued a simple reminder to investors.

  • Business Wire2 months ago

    BioTime to Announce Second Quarter 2018 Results on August 2, 2018

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, August 2, 2018, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and recent corporate developments. The live webcast can be accessed on the “Events & Presentations” page of the “Investors & Media” section on the company’s website.

  • BioTime (BTX) in Focus: Stock Moves 7.3% Higher
    Zacks2 months ago

    BioTime (BTX) in Focus: Stock Moves 7.3% Higher

    BioTime (BTX) was a big mover last session, as the company saw its shares rise more than 7% on the day.

  • Business Wire2 months ago

    AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 12 in New York City

    AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will present at the conference Ending Age-Related Diseases: Investment Prospects & Advances in Research, Thursday, July 12 at Cooper Union in New York City. Scheduled for 2:00pm EDT, Dr. West’s presentation, “Hayflick Rewound: Somatic Restriction, Epigenetics, and the Reversibility of Human Aging” will describe AgeX’s induced Tissue Regeneration (iTRTM) program and its potential clinical application.

  • Business Wire2 months ago

    BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the record date for the distribution of AgeX Therapeutics (“AgeX”) shares owned by BioTime on a pro rata basis to eligible BioTime shareholders.

  • Business Wire3 months ago

    BioTime Awarded Grant From the NIH

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has been awarded a grant of $743,345 from the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH). This award constitutes the second-year funding of a $1.6 million SBIR grant to advance BioTime’s innovative, next generation retinal restoration program addressing advanced retinal diseases and injuries, which impact the quality of life for millions of people with no treatment options. “This NIH grant program is incredibly competitive, so this award provides further validation of our advances in retinal restoration initiatives, in a continued effort to develop a robust pipeline of cell therapy products for ophthalmology,” said Francois Binette, Ph.D., Sr Vice President and Head of Global Development at BioTime.

  • Should You Expect Forbuild SA (WSE:BTX) To Continue Delivering An ROE Of 10.89%?
    Simply Wall St.3 months ago

    Should You Expect Forbuild SA (WSE:BTX) To Continue Delivering An ROE Of 10.89%?

    This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between Forbuild SA (WSE:BTX)’s return fundamentalsRead More...

  • Business Wire3 months ago

    BioTime Licenses GMP Cell Line to Goliver Therapeutics

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver Therapeutics, a France-based company focused on addressing liver diseases with regenerative technologies. “We are excited to help enable the team at Goliver to further their mission to treat liver diseases with differentiated cells created from one of our cell lines,” stated Adi Mohanty, Co-CEO of BioTime. Various cell lines of ours are being used by researchers around the world.